ResApp Health has announced additional positive results from its clinical study on the use of its smartphone app to diagnose and manage respiratory disease.
ResApp Health announced additional positive results from its clinical study evaluating ResApp’s technology in adults with chronic obstructive respiratory disease (COPD), asthma, pneumonia, and upper respiratory tract infection (URTI).
ResApp is a smartphone application for the diagnosis and management of respiratory disease. The technology is based on machine-learning algorithms that use sound to diagnose and measure the severity of respiratory conditions without requiring additional hardware. ResApp is currently undergoing adult and pediatric clinical trials with preliminary results demonstrating promising accuracy in the diagnosis of COPD, asthma, pneumonia, and URTI.
An adult trial is now underway at Joondalup Health Campus (JHC) and the Wesley Hospital in Australia. This set of preliminary results was analyzed by a research team led by Udantha Abeyratne, associate professor at the University of Queensland.